Effects of alendronate on bone density in men with primary and secondary osteoporosis

Osteoporosis International

Volumn 11, Issue 2, 2000, Pages 98-101

  Ho, Y V ^a   Frauman, A G ^a   Thomson, W M ^a   Seeman, E ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Alendronate; Bone mineral density; Men; Osteoporosis

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; VERTEBRA FRACTURE;

EID: 0034066105     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004182     Document Type: Article

References (19)

1. Seeman E. Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities. Am J Med 1993;95:s22-8.
2. Davies KM, Stegman MR, Heaney RP, Recker RR. Prevalence and severity of vertebral fracture: the Saunders County Bone Quality Study. Osteoporos Int 1996;6:160-5.
3. Jones G, White C, Nguyen T, Sambrook PN, Kelly PJ, Eisman JA. Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int 1996;6:233-9.
4. Tsai KS, Twu SJ, Chieng PU, Yang RS, Lee TK. Prevalence of vertebral fractures in Chinese men and women in Urban Taiwanese communities. Calcif Tissue Int 1996;59:249-53.
5. Burger H, Van Daele PL, Grashuis K, Hofman A, Grobbee DE, Schutter HE, et al. Vertebral deformities and functional impairment in men and women. J Bone Miner Res 1997;12:152-7.
6. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
7. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
8. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
9. Heaney RP, Yates JA, Santora AC II. Bisphosphonate affects the bone remodeling transient. J Bone Miner Res 1997;12:1143-51.
10. Sisson de Castro JA. Alendronate treatment of osteoporosis in men: short term bone mass response. J Bone Miner Res 1996;11:s341.
11. Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993;53:283-8.
12. Azuma Y, Chokki M, Ohta T, Kiyoki M. Effects of alendronate on plasma calcium levels, urinary calcium excretion, and bone resorption markers in normal rats: comparison with elcatonin, synthetic eel calcitonin. Endocrinology 1996;137:2586-92.
13. Sass DA, Bowman AR, Yuan Z, Ma Y, Jee WS, Epstein S. Alendronate prevents cyclosporin A-induced osteopenia in the rat. Bone 1997;21:65-70.
14. Orme S, Simpson M, Stewart S, Oldroyd B, Westmacott C, Smith M, et al. Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. Clin Endocrinol 1994;41:245-50.
15. Anderson F, Francis R, Bishop J, Rawling D. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. Age and Ageing 1997;26:359-65.
16. Rajan K, Evans W, Blacker M. Male osteoporosis. Bone Miner 1994;25:s39.
17. Geusens P, Nijs J, Joly J, Dequeker J. Cyclic etidronate and calcium in male osteoporosis. J Bone Miner Res 1994;9 (Suppl 1):S397.
18. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
19. Valkema R, Vismans FJ, Papapoulos SE, Pauwels EK, Bijvoet OL. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989;5:183-92.